Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...
-
ICON releases environmental, social and governance report
ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.
-
ICON announces the expansion of its Accellacare Site Network
New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability.
-
ICON reports third quarter 2021 financial results
Quarter 3 adjusted revenue of $1,870.4 million representing a year on year increase of 167% or 165% on a constant currency basis.
-
Tánaiste announces multi-million euro R&D support of ICON to accelerate decentralised clinical trial technology
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants.
-
ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
-
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customer’s commercial success through the development of medicines and medical devices.
-
ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting
All resolutions at the ICON Extraordinary General Meeting held on June 15, 2021 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.
-
ICON reports first quarter 2021 results
Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28.
-
ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row
ICON received 2021 CRO Leadership Awards. ICON achieved awards in both the Big Pharma and Overall groups.
-
ICON reports fourth quarter and full year 2020 results
Record net business wins in the quarter of $1,080 million; a book to bill of 1.42. Full year net business wins of $3.8 billion; a net book to bill of 1.38.
